Targeted cargo protein combination therapy

Abstract

The present invention combines a targeted cargo protein with an active agent for the treatment of a disease or condition.

1 - 35 . (canceled) 
     
     
         36 . A method of inhibiting a cancer cell that overexpresses an IL-4 receptor, comprising:
 a. contacting said cancer cell with a targeted cargo protein comprising a targeting moiety that specifically binds to an IL-4 receptor, and a cargo moiety that inhibit said cancer cell, and   b. contacting said cancer cell with an active agent.   
     
     
         37 . The method of  claim 36 , wherein the targeted cargo protein is selected from the group consisting of IL4-BAD and IL-13-BAD, and variants thereof. 
     
     
         38 . The method of  claim 36 , wherein the cargo moiety is selected from pro-apoptotic members of the Bcl-2 family of proteins which include but are not limited to BAX, BAD, BAT, BAK, BIK, BID BIM, BMF, and BOK, and variants thereof. 
     
     
         39 . The method of  claim 36 , wherein the cargo moiety is selected from non-Bcl-2 family of pro-apoptotic proteins which include but are not limited to granzymes and caspases and variants thereof. 
     
     
         40 . The method of  claim 36 , wherein said cancer cell is a cell of a cancer selected from the group consisting of brain cancer, a hematological cancer, Kaposi sarcoma, bladder cancer, renal cell cancer, breast cancer, pancreatic cancer, non-small cell lung cancer, thyroid cancer, squamous cell carcinoma of the head and neck, colon cancer, bile duct carcinoma, ovarian cancer, a cancer of the gastrointestinal system, mesothelioma, rhabdomyosarcoma, and prostate cancer. 
     
     
         41 . The method of  claim 36 , wherein said cancer cell is selected from the group consisting of a malignant astrocytoma cell, a medulloblastoma cell, a meningioma cell, and a glioma cell. 
     
     
         42 . The method of  claim 36 , wherein said active agent is selected from the group consisting of gemcitabine, doxorubicin, FOLFOX (folinic acid, fluorouracil, and oxaliplatin), premetrexed, irinotecan, temozolamide, cisplatin, oxaliplatin, erlotinib, imatinib, cetuximab, bevacizumab, rituximab, an antibody, or other active agent used to treat cancer.